<DOC>
	<DOCNO>NCT00670241</DOCNO>
	<brief_summary>This study compare efficacy safety daily treatment calcipotriol plus betamethasone dipropionate gel ( LEO 80185 ) tacalcitol ointment LEO 80185 vehicle alone subject psoriasis vulgaris . Subjects treat 8 week follow observation period 8 week investigate occurence time relapse occurence rebound discontinuation investigational product . Only subject `` controlled disease '' consider observation phase study . `` Controlled disease '' define `` Clear '' `` Almost Clear '' severity category base Investigator 's global assessment ( IGA ) .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment Gel Vehicle Alone Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>1 alpha,24-dihydroxyvitamin D3</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<criteria>Signed date informed consent obtain prior trial related procedure , include washout Clinical diagnosis psoriasis vulgaris involve trunk and/or arm and/or legs amenable treatment maximum 100 g LEO 80185 gel per week 10 g per day tacalcitol ointment Disease severity grade moderate , severe severe accord Investigator 's global assessment ( IGA ) disease severity A minimum PASI score extent 2 least one body region ( i.e.psoriasis affect least 10 % arm , and/or 10 % trunk , and/or 10 % leg ) Subjects age 18 year Either sex Any ethnic origin Attending hospital outpatient clinic private practice dermatologist Systemic treatment biological therapy ( market market ) , possible effect psoriasis vulgaris ( e.g. , alefacept , efalizumab , etanercept , infliximab , adalimumab ) within 3 month prior randomisation Systemic treatment therapy biologics , possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4 week prior randomisation Systemic treatment Vitamin D preparation 500 IU per day PUVA Grenz ray therapy within 4 week prior randomization UVB therapy within 2 week prior randomisation Any topical treatment trunk/limbs ( except emollient ) within 2 week prior randomisation Topical treatment relevant skin disorder face flexure ( e.g. , facial flexural psoriasis , eczema ) potent potent ( WHO group IIIIV ) corticosteroid vitamin D analogue within 2 week prior randomisation Topical treatment relevant skin disorder scalp ( e.g . scalp psoriasis ) potent ( WHO group IV ) corticosteroid vitamin D analogue within 2 week prior randomisation Planned initiation , change concomitant medication could affect psoriasis vulgaris ( e.g. , beta blocker , ACE inhibitor , antimalaria drug , lithium ) study Current diagnosis erythrodermic , exfoliative pustular psoriasis Subjects follow condition present treatment area : viral ( e.g. , herpes varicella ) lesion , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , acne rosacea , ulcer wound Known suspect disorder calcium metabolism associate hypercalcaemia Known suspect severe renal insufficiency severe hepatic disorder Known suspected hypersensitivity component ( ) Investigational Products Current participation interventional clinical study Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4week period prior randomisation , except biologics ( 3 month ) Planned exposure sun study may affect psoriasis vulgaris Previously randomise study Subjects know suspect able comply trial protocol ( e.g . due alcoholism , drug dependency psychotic state ) Females childbearing potential wishing become pregnant study , breastfeeding , use adequate method contraception study Females childbearing potential positive pregnancy test Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>